{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004474","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.568067+00:00","generated_at":"2026-05-18T06:35:07.099189+00:00","sec_items":["7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptose receives $2M advance from Hanmi under $8.5M loan facility for tuspetinib AML trial","bullets":["Second advance brings total drawn to $4.5M under the $8.5M loan agreement with Hanmi.","Funds directed to ongoing TUSCANY Phase 1/2 study of tuspetinib triplet therapy in newly diagnosed AML.","Tuspetinib combination with venetoclax/azacitidine showed safety and MRD negativity in early data.","Loan facility announced June 20, 2025; proceeds extend Aptose's cash runway for clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004474","json":"https://secwatch.observer/filing/0001171843-25-004474.json","markdown":"https://secwatch.observer/filing/0001171843-25-004474.md","text":"https://secwatch.observer/filing/0001171843-25-004474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325004474/0001171843-25-004474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325004474/f8k_071525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:35:07.099189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}